Viatris (WBO:MYL) 3-Year Book Growth Rate : -3.60% (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Viatris 3-Year Book Growth Rate?

Viatris's Book Value per Share for the quarter that ended in Sep. 2024 was €14.94.

During the past 12 months, Viatris's average Book Value per Share Growth Rate was -4.70% per year. During the past 3 years, the average Book Value per Share Growth Rate was -3.60% per year. During the past 5 years, the average Book Value per Share Growth Rate was -7.10% per year. During the past 10 years, the average Book Value per Share Growth Rate was 5.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Viatris was 49.30% per year. The lowest was -13.10% per year. And the median was 14.50% per year.

Competitive Comparison of Viatris's 3-Year Book Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viatris's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Viatris's 3-Year Book Growth Rate falls into.

Viatris 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Viatris (WBO:MYL) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Viatris 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Viatris's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (WBO:MYL) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

VTRS:USA MYL:Mexico 1VTRS:Italy 0A5V:UK VIA:Germany VIA:Germany VIA:Germany VIA:Germany

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris Headlines

No Headlines